Q1 2024 13F Holders as of 3/31/2024
-
Type / Class
-
Equity / Common Stock, $0.001 par value per share
-
Shares outstanding
-
49.1M
-
Number of holders
-
72
-
Total 13F shares, excl. options
-
44.5M
-
Shares change
-
+5.48M
-
Total reported value, excl. options
-
$781M
-
Value change
-
+$95.5M
-
Number of buys
-
40
-
Number of sells
-
-23
-
Price
-
$17.59
Significant Holders of Enliven Therapeutics, Inc. - Common Stock, $0.001 par value per share (ELVN) as of Q1 2024
74 filings reported holding ELVN - Enliven Therapeutics, Inc. - Common Stock, $0.001 par value per share as of Q1 2024.
Enliven Therapeutics, Inc. - Common Stock, $0.001 par value per share (ELVN) has 72 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 44.5M shares
of 49.1M outstanding shares and own 90.6% of the company stock.
Largest 10 shareholders include ORBIMED ADVISORS LLC (9M shares), FMR LLC (6.25M shares), VR Adviser, LLC (4.03M shares), COMMODORE CAPITAL LP (3.97M shares), 5AM Venture Management, LLC (3.84M shares), Fairmount Funds Management LLC (3.2M shares), CITADEL ADVISORS LLC (2.35M shares), RA CAPITAL MANAGEMENT, L.P. (2.12M shares), BlackRock Inc. (1.81M shares), and Logos Global Management LP (1.57M shares).
This table shows the top 72 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.